CIMT: Why a Normal Stress Test Doesn't Rule Out Plaque

A patient in his late forties arrives with a clean bill of health. Blood pressure is fine, he does not smoke, his cholesterol is unremarkable, and a treadmill stress test two years ago was normal. His ten-year risk score puts him in the low-to-intermediate band, which in practice means his physician has nothing concrete to act on. Then a fifteen-minute ultrasound of his neck shows a discrete plaque in the left carotid bulb. Nothing about his numbers changed. Every clinical decision that follows does.

That scan is carotid intima-media thickness imaging — CIMT — and it belongs to a small category of tests that replace a statistical estimate with a direct observation. Risk calculators tell you what happens to people who resemble you. Arterial imaging tells you what has happened to your arteries.

What a CIMT scan actually measures

The carotid artery wall has three layers. The innermost two — the intima and the media — sit directly beneath the vessel lumen and thicken together in response to ageing, hypertension, and lipid deposition. High-resolution B-mode ultrasound resolves the boundary between blood and intima and the boundary between media and adventitia with enough precision to measure the distance between them, typically in the far wall of the distal common carotid artery, in fractions of a millimetre.

The examination is genuinely undemanding. A linear transducer, ultrasound gel, ten to fifteen minutes lying flat with the head turned. No radiation, no contrast, no cannula, no fasting, no recovery. Modern systems use automated edge-detection software and ECG gating so that measurements are taken at the same point in the cardiac cycle, which is what makes the result reproducible enough to repeat in a year or three.

The result comes in two parts, and they are not the same thing: a thickness measurement, usually reported as a percentile for age and sex, and a separate report of whether discrete plaque is present anywhere in the scanned segments.

Why a normal stress test does not rule out early atherosclerosis

This is the most consequential misunderstanding in preventive cardiology, and it is not the patient's fault. A stress test — treadmill, stress echo, nuclear perfusion — is designed to answer one question: is there a narrowing severe enough to starve the heart muscle of blood when demand rises? Ischaemia generally becomes detectable only once a coronary artery is narrowed on the order of seventy percent. A stress test is therefore an excellent test for advanced, flow-limiting disease and a poor one for everything that precedes it.

Atherosclerosis, meanwhile, has been under way for decades. Autopsy studies of young people who died of unrelated causes — trauma, accidents, military casualties — have consistently found fatty streaks and early raised lesions in the aorta and coronary arteries of adolescents and adults in their twenties. Contemporary imaging cohorts of asymptomatic middle-aged adults with low conventional risk scores find subclinical plaque in a substantial proportion of them.

Compounding this, arteries actively hide their disease. As plaque accumulates, the vessel remodels outward — the wall expands away from the lumen so that the channel for blood stays open. This compensatory enlargement means an artery can carry a meaningful plaque burden while an angiogram, and any test that depends on flow, reads as normal. Worse, the plaques most likely to rupture and cause a myocardial infarction are frequently not the tightly stenotic ones. They are lipid-rich, inflamed, and often barely narrowing the lumen at all.

A normal stress test means you are not currently limited by a severe blockage. It does not mean your arteries are clean. Those are different statements, and only one of them is being tested.

Wall thickness versus plaque — and why the distinction matters

Intima-media thickness itself is best understood as a marker of cumulative arterial exposure — to blood pressure, to lipoprotein burden, to glycaemic stress, to time. It rises gradually with age in everyone. A thickness above roughly the seventy-fifth percentile for a patient's age and sex is conventionally treated as elevated, and it shifts the risk conversation, but it is a graded, statistical signal rather than a diagnosis.

Plaque is categorically different. Under the widely used consensus definition, plaque is a focal structure encroaching into the arterial lumen — measuring at least 1.5 mm, or protruding at least 0.5 mm or fifty percent beyond the surrounding wall thickness. Its presence is not a percentile on a curve. It is a lesion. Across large cohort studies, the presence and extent of carotid plaque predicts cardiovascular events more strongly than intima-media thickness measured alone, and a scan reporting diffuse thickening with no plaque should be read very differently from one reporting a discrete plaque in the bulb.

Practically, this means the useful question to ask about a CIMT report is not only "what was my number?" but "was there plaque, where, and how much?"

CIMT and coronary calcium: complementary, not competing

Coronary artery calcium (CAC) scoring is the other widely used structural test, and it is the one with the strongest guideline backing. A brief non-contrast CT quantifies calcified plaque in the coronary arteries and returns a single score. Its value for risk reclassification is well established: in large prospective cohorts, adding CAC to conventional risk factors moves a meaningful number of intermediate-risk patients decisively up or down, and a score of zero in an appropriately selected middle-aged or older adult carries a genuinely reassuring short-to-medium-term prognosis.

Its limitation is intrinsic to what calcium is. Calcification is a relatively late, healing-phase feature of atherosclerosis. Soft, non-calcified plaque — the biologically active kind — does not register. In a forty-year-old with a strong family history, a calcium score of zero may simply mean the disease has not yet calcified. Carotid ultrasound, which images the wall directly rather than a mineral deposit within it, can show change earlier, involves no radiation, and can therefore be repeated freely.

Who benefits most from arterial imaging

Imaging is most valuable where the decision is genuinely uncertain — where a risk score sits in the grey zone and the answer will change management. The patients in whom it most often earns its place:

• Intermediate calculated risk. The population in which guidelines explicitly call for a tiebreaker, because the case for starting long-term therapy is otherwise finely balanced.
• Premature family history. A parent or sibling with coronary disease in their forties or fifties, particularly when the patient's own conventional risk factors look benign.
• Elevated Lp(a). Lipoprotein(a) is largely genetically fixed, atherogenic in its own right, and poorly represented in standard risk calculators. Imaging tells you whether that inherited exposure has already produced structural disease.
• Younger patients where calcium is likely to be uninformative. Adults in their thirties and forties, in whom a CAC of zero is expected and therefore says little.
• Patients who need to see it. Ambivalence about decades of preventive therapy often resolves the moment an abstract percentage becomes a visible lesion.

What changes clinically when plaque is found

Finding plaque does not make anyone acutely ill. It reclassifies them. A person with documented subclinical atherosclerosis is no longer someone with a probability of developing the disease; they are someone who has it, early, and asymptomatically. That distinction drives several concrete changes.

Lipid targets tighten. Where an ApoB below 80 mg/dL might have been a reasonable goal on statistical risk alone, demonstrated plaque generally justifies pushing toward ApoB below 65 mg/dL — the goal European guidelines attach to the very-high-risk category, alongside an LDL-C below 55 mg/dL. The threshold for initiating pharmacotherapy drops, and the case for sustaining it over decades becomes much easier to make honestly. Blood pressure and glycaemic control are pursued with less latitude. And the scan becomes a baseline: a repeat study in two or three years shows whether the trajectory has been altered.

What it does not do is predict an event on any timescale, or convert prevention into a guarantee. Atherosclerosis is modifiable, and the evidence that lowering atherogenic particle burden reduces events is among the most robust in medicine — but modifying a disease is not the same as eliminating it.

The honest limitations of CIMT

Carotid ultrasound is not a universally endorsed screening test, and it would be misleading to present it as one.

• It is operator-dependent. Image quality, probe angle, which segments are interrogated, and the software used all affect the result. A CIMT performed by an untrained sonographer on unstandardised equipment is close to worthless. Comparisons across laboratories are unreliable.
• Its incremental value is contested. Large pooled analyses have found that adding common-carotid intima-media thickness to conventional risk factors improves prediction only marginally, and some major guideline bodies have consequently stopped recommending it for routine risk assessment. The evidence for carotid plaque is stronger than for thickness alone — a distinction the guideline language does not always make cleanly.
• Change over time is not a validated treatment surrogate. Trials that used intima-media thickness progression as an endpoint have not reliably tracked clinical outcomes. A stable measurement is reassuring; it is not proof that therapy is working.
• The carotid is a proxy. It is an accessible artery standing in for an inaccessible one. Carotid and coronary disease correlate, but not perfectly.

None of this makes the test unhelpful. It makes it a test to interpret carefully, in a patient selected for a reason, alongside the rest of the picture — rather than a number to collect.

What to ask your physician

If arterial imaging is being considered, a few questions will make the result far more useful:

• Will this change what we do? If the answer is no — if therapy is already maximal, or the decision is already made — the scan is interesting rather than useful.
• Was plaque present, or only thickening? Ask for both findings explicitly. They carry different weight.
• Which test fits my age? Calcium scoring is generally the stronger choice in older adults; carotid ultrasound is more informative when calcium is likely to read zero regardless.
• What are my ApoB and Lp(a)? Imaging identifies the damage. Particle burden explains much of what is causing it, and is what treatment actually targets.
• When should this be repeated? A single scan is a snapshot. Its value compounds when it becomes a trajectory.

The argument for looking at the arteries is not that imaging is novel. It is that cardiovascular disease spends most of its natural history silent, and that the first symptom is too often the event itself. Looking earlier does not guarantee a better outcome. It does make the intervening decades a matter of evidence rather than estimation.